Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 15/20 | 0.52 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.50 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.50 |
| ▸ | GAK | O14976 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5320281 | 0.80 | EGFR (0.80) | EGFRERBB2ERBB3ERBB4GAK | |
| SCHEMBL1095136 | 0.76 | EGFR (0.82) | EGFRERBB2ERBB3ERBB4GAK | |
| SCHEMBL4268667 | 0.76 | SRC (0.58) | EGFRERBB2 | |
| SCHEMBL4268138 | 0.76 | DYRK1A (0.43) | EGFRERBB2KDM4EGAA | |
| SCHEMBL4262118 | 0.74 | ERBB2 (0.62) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL28347182 | 0.72 | EGFR (0.74) | EGFRERBB2ERBB3ERBB4GAK | |
| SCHEMBL4266452 | 0.71 | TTBK1 (0.47) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL4261215 | 0.70 | EGFR (0.63) | EGFRERBB2ERBB4 | |
| SCHEMBL4264957 | 0.69 | ERBB2 (0.60) | EGFRERBB2 | |
| SCHEMBL6977418 | 0.69 | EGFR (0.75) | EGFRERBB2ERBB3ERBB4GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579356-B2 | Thia-tetraazaacenaphthylene kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-25 | — | — | US | disclosed |
| US-20070265264-A1 | 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| WO-2006118749-A1 | THIA-TETRAAZAACENAPHTHYLENE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265264-A1 | 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide | ADK, MAP3K9, MAP4K5 | EGFR 488/4885ERBB2 67/4885ERBB3 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.